Erythroderma Desquamativa of Leiner

Erythroderma Desquamativa of Leiner

National Organization for Rare Disorders, Inc.

Important

It is possible that the main title of the report Erythroderma Desquamativa of Leiner is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.

Synonyms

  • Erythroderma Desquamativum of Infancy
  • Leiner-Moussous Desquamative Erythroderma
  • Leiner Disease

Disorder Subdivisions

  • None

General Discussion

Erythroderma desquamativa of Leiner is a rare skin disorder that usually first appears during the end of the first month of life or the beginning of the second month. The disorder is characterized by the appearance of a reddish, thickened rash on various parts of an infant's body. Additional symptoms include chronic diarrhea and the failure to gain weight at the expected rate (failure to thrive). The exact cause of erythroderma desquamativa of Leiner is unknown.

Symptoms

The skin abnormalities associated with erythroderma desquamativa of Leiner resemble seborrheic dermatitis, a chronic inflammatory skin disease.



The initial symptom of erythroderma desquamativa of Leiner is the appearance of a thick, reddish rash. Redness (erythroderma) may be followed after a few days by crusty, dry, moist or greasy scaling or yellow, crusted patches of skin. In many cases, itching is often associated with the rash.



Additional symptoms associated with erythroderma desquamativa of Leiner include chronic diarrhea, failure to thrive and weight loss. Infants with erythroderma desquamativa of Leiner may also be more susceptible to infections and may experience repeated infections. The disorder may last from several weeks to several months.

Causes

The exact cause of erythroderma desquamativa of Leiner is unknown. Considerable debate and confusion as to the potential cause(s) and development of the disorder exists in the medical literature.



Some researchers believe that nutritional deficiencies such as biotin, a substance that is more prevalent in cow's milk than human milk, may play a role in the development of erythroderma desquamativa of Leiner. Researchers have also speculated that the disorder may be influenced by unknown toxic substances either passed to infants through breast milk or originating in their intestinal tracts.



In some cases, abnormalities of the immune system may also be a factor in the development of erythroderma desquamativa of Leiner. The specific immunological defect is a modification of blood complement C5, which governs the body's reaction to infection. The significance of this finding in relation to the disorder is not known.



Some cases of erythroderma desquamativa of Leiner may be inherited as an autosomal recessive genetic trait. Human traits, including the classic genetic diseases, are the product of the interaction of two genes, one received from the father and one from the mother.



In recessive disorders, the condition does not appear unless a person inherits the same defective gene for the same trait from each parent. If an individual receives one normal gene and one gene for the disease, the person will be a carrier for the disease, but usually will not show symptoms. The risk of transmitting the disease to the children of a couple, both of whom are carriers for a recessive disorder, is 25 percent. Fifty percent of their children risk being carriers of the disease, but generally will not show symptoms of the disorder. Twenty-five percent of their children may receive both normal genes, one from each parent, and will be genetically normal (for that particular trait). The risk is the same for each pregnancy.

Affected Populations

Erythroderma desquamativa of Leiner is a rare disorder that usually affects infants during the first two months of life. According to the medical literature, breastfed infants seem to have a higher incidence of this disorder than those who are on formulas. Males and females are affected in equal numbers. More than 50 cases have been reported in the medical literature.



Erythroderma desquamativa of Leiner was first described by Dr. Carl Leiner in 1908. The disorder eventually became known as Leiner disease. Through the years, the term "Leiner disease" has been used to describe a wide spectrum of disorders associated with erythroderma, resulting in considerable confusion within the medical literature as to the proper usage of "Leiner disease." As a result, many physicians have suggested avoiding or abandoning the term "Leiner disease."

Standard Therapies

The treatment of Leiner disease is symptomatic and supportive. Antibiotics, vitamins, and monitoring of fluid and food intake have been used to treat the disorder. In some cases, after a few weeks, redness and scaliness decrease with careful treatment and do not usually recur.

Investigational Therapies

Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.



For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:



Tollfree: (800) 411-1222

TTY: (866) 411-1010

Email: prpl@cc.nih.gov



For information about clinical trials sponsored by private sources, contact:

www.centerwatch.com

References

TEXTBOOKS

Behrman RE., ed. Nelson Textbook of Pediatrics, 15th ed. Philadelphia, PA: W.B. Saunders Company; 1996:1859.



Champion RH, et al., eds. Textbook of Dermatology. 5th ed. Cambridge, MA: Blackwell Scientific Publications; 1992:441-2.



Magalini SI, et al., eds. Dictionary of Medical Syndromes. 4th ed.New York, NY: Lippincott-Raven Publishers; 1997:481.



Buyce ML., ed. Birth Defects Encyclopedia. Dover, MA: Blackwell Scientific Publications; For: The Center for Birth Defects Information Services Inc; 1990:958.



JOURNAL ARTICLES

Itani O, et al., Picture of the month. Ritter's disease (neonatal staphylococcal scalded skin syndrome). Am J Dis Child. 1992;146:425-6.



de Saint-Basile G, et al., Restricted heterogeneity of T lymphocytes in combined immunodeficiency with hypereosinophilia (Omenn's syndrome). J Clin Invest. 1991;87:1352-9.



Goodyear HM, et al., Leiner's disease associated with metabolic acidosis. Clin Exp Dermatol. 1989;14:364-6.



Glover MT, et al., Syndrome of erythroderma, failure of thrive, and diarrhea in infancy: a manifestion of immunodeficiency. Pediatrics. 1988;81:66-72.



Sonea MJ, et al., Leiner's disease associated with diminished third component of complement. Pediatr Dermatol. 1987;4:105-7.



Guenther L, et al., Inherited disorders of complement. J Am Acad Dermatol. 1983;9:815-39.



Evans DI, et al., Yeast opsonization defect and immunoglobulin deficiency in severe infantile dermatitis (Leiner's disease). Arch Dis Child. 1977;52:691-95.



FROM THE INTERNET

McKusick VA., ed. Online Mendelian Inheritance in Man (OMIM). Baltimore. MD: The Johns Hopkins University; Entry No:2271000; Last Update:2/18/99. Entry Number:256500; Last Update:11/9/99.

Resources

March of Dimes Birth Defects Foundation

1275 Mamaroneck Avenue

White Plains, NY 10605

Tel: (914)997-4488

Fax: (914)997-4763

Tel: (888)663-4637

Email: Askus@marchofdimes.com

Internet: http://www.marchofdimes.com



NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases

Information Clearinghouse

One AMS Circle

Bethesda, MD 20892-3675

USA

Tel: (301)495-4484

Fax: (301)718-6366

Tel: (877)226-4267

TDD: (301)565-2966

Email: NIAMSinfo@mail.nih.gov

Internet: http://www.niams.nih.gov/



Genetic and Rare Diseases (GARD) Information Center

PO Box 8126

Gaithersburg, MD 20898-8126

Tel: (301)251-4925

Fax: (301)251-4911

Tel: (888)205-2311

TDD: (888)205-3223

Internet: http://rarediseases.info.nih.gov/GARD/



Madisons Foundation

PO Box 241956

Los Angeles, CA 90024

Tel: (310)264-0826

Fax: (310)264-4766

Email: getinfo@madisonsfoundation.org

Internet: http://www.madisonsfoundation.org



For a Complete Report

This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into myCigna.com. For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html.

This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use . How this information was developed to help you make better health decisions.

Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.